Efficacy and Safety of Pirfenidone Capsules in the Treatment of Pneumoconiosis

NCT05288179

Status	RECRUITING
Phase	Phase 3
Sponsor	Beijing Continent Pharmaceutical Co, Ltd.
Enrollment	272 participants

Key Eligibility Criteria

Inclusion (21)

- \. Age 18\~70 years old (including 18 years old and 70 years old), gender is not limited.
- \. Diagnosed with silicosis or coal worker's pneumoconiosis, in line with GBZ 70-2015 "Diagnosis of Occupational Pneumoconiosis".
- \. Forced vital capacity at screening percentage of predicted value %FVCe40% and \<80% 4. The percentage of carbon monoxide dispersion in the predicted value at the time of screening %DLCOe30% and \<80%.
- HRCT at screening showed diffuse interstitial changes in the lungs. 6. Patients voluntarily participated in this trial, with good compliance, and had the ability to understand and sign informed consent before the study.
- \. ALT or AST \> 3 times ULN. 4. TBiL \> 2 times ULN. 5. Creatinine clearance \<30 mL/min. 6. Patients with co-infection or high fever within 4 weeks prior to screening, including but not limited to acute bronchitis, pneumonia, sinusitis, urinary tract infection, or cellulitis.

... and 16 more (see full listing online)

Locations (1 total)

Beijing China-Japan Friendship Hospital, Beijing, China